Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D JohnstonNadia HarbeckRoberto HeggMasakazu ToiMiguel MartinZhi Min ShaoQing Yuan ZhangJorge Luis Martinez RodriguezMario CamponeErika Paige HamiltonJoohyuk SohnValentina GuarneriMorihito OkadaFrances BoylePatrick NevenJavier CortesJens HuoberAndrew WardleySara M TolaneyIrfan CicinIan C SmithMartin FrenzelDesirée HeadleyRan WeiBelen San AntonioMaarten HulstijnJoanne CoxJoyce O'ShaughnessyPriya Rastoginull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Abemaciclib when combined with ET is the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS in patients with HR+, HER2- node-positive EBC at high risk of early recurrence.